Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

LLM 2021 | Upcoming regimens in MCL

Natalie Grover • 15 Oct 2021
LLM 2021
Lymphoma Mantle Cell Lymphoma Brexucabtagene autoleucel BTK inhibitors CAR-T Lisocabtagene maraleucel Pirtobrutinib

Natalie Grover, MD, UNC School of Medicine, Chapel Hill, NC, discusses regimens on the horizon in mantle cell lymphoma (MCL). Upcoming treatment strategies include CAR T-cell therapies, such as lisocabtagene maraleucel, bispecific CAR T-cells targeting CD19 and CD20, as well as combinations with CAR-T and Bruton’s tyrosine kinase (BTK) inhibitors. Additionally, pirtobrutinib, a non-covalent BTK inhibitor, has shown promising results in patients with relapsed/refractory MCL. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.

Disclosures

Consulting: Tessa and Novartis
Advisory board: ADC therapeutics and Kite
Research funding: Genentech

More from Natalie Grover

CD30, a promising target for CAR-T therapy in Hodgkin lymphoma
1:15
CD30, a promising target for CAR-T therapy in Hodgkin lymphoma
Natalie Grover • 28 Apr 2022
CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCL
4:06
CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCL
Natalie Grover • 28 Apr 2022
The role of transplant in MCL in the era of cellular therapy
1:00
The role of transplant in MCL in the era of cellular therapy
Natalie Grover • 15 Oct 2021
Future directions for CAR T-cell therapy in MCL
1:40
Future directions for CAR T-cell therapy in MCL
Natalie Grover • 15 Oct 2021

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals